Economic Evaluation of Generic Tacrolimus and Innovator in Renal Transplant Recipients in Egypt
Author(s)
Elsisi G1, Elsharkawy M2, Salah M3, Mohamed W4, Moustafa N4, Elabbassy M5, Abdel-Rahman R5, Roshdy A6, Ahmed E7, Mohamed H8, El ghandour S9, Telep F10, Hafez M11
1The American University in Cairo, cairo, C, Egypt, 2Ain Shams University, Cairo, Egypt, 3National Institute for Kidney and Urology, cairo, Egypt, 4El-amana Specialized Medical Centers, cairo, Egypt, 5Nasser Institute, cairo, Egypt, 6Fatimmya Cairo Hospital, cairo, Egypt, 7Dar Elsalam oncology center, cairo, Egypt, 8Sheikh Zayed specialized Hospital, cairo, Egypt, 9Sheikh Zayed specialized Hospital, Cairo , C, Egypt, 10HTA office, cairo, Egypt, 11Cairo University, cairo, Egypt
Presentation Documents
OBJECTIVES:
Both brand and generic tacrolimus proved to have the same quality, efficacy, safety and pharmacokinetics properties.
We conducted a cost minimization analysis to estimate the direct medical costs of adopting the generic tacrolimus compared to the innovator from a payer perspective in the Egyptian renal transplant recipients over one year.
METHODS:
We compared the cost and consequences of the generic tacrolimus versus the innovator in renal transplant recipients from the payer perspective in three transplant centers in Egypt including 120 patients over one year. Clinical data were extracted from a retrospective observational and database analysis study of renal transplant patients in different European countries. We considered the cost of hospitalization, secondary events management, medications, and follow-up tests. All costs were presented in Egyptian Pounds (EGP) in financial year 2022. The unit costs were captured from the Ministry of Health and the resource utilization was validated from Expert Panel. One-way sensitivity analyses were conducted to ensure the robustness of our results.RESULTS:
In the management of post kidney transplant patients, using generic tacrolimus is associated with lower costs compared to the innovator. Average direct medical costs per patient in one year in generic tacrolimus and innovator were EGP 135,778 and EGP 168,935, respectively. For the total population, the cost was estimated as EGP 16,293,378 and EGP 20,272,266 for the generic tacrolimus and innovator, respectively. Generic tacrolimus resulted in EGP 3,978,888 savings.CONCLUSIONS:
The study results showed a reduction in costs upon using generic tacrolimus compared to the innovator in post kidney transplantation. Our results suggest that generic tacrolimus is cost saving with the same efficacy and safety in the prevention of post-transplant events. These findings can assist the policy and decision makers when considering the value of conversion from innovator to generic.Conference/Value in Health Info
Value in Health, Volume 25, Issue 12S (December 2022)
Code
EE288
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
SDC: Urinary/Kidney Disorders